Listar por autor "Grande, Enrique"
Mostrando ítems 1-2 de 2
-
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis
Capdevila, Jaume; Sevilla, Isabel; Alonso, Vicente; Antón-Aparicio, Luis M.; Jiménez Fonseca, Paula; Grande, Enrique; Reina, Juan José; Manzano, José Luis; Alonso Lájara, Juan Domingo; Barriuso, Jorge; Castellano, Daniel; Medina, Javier; López, Carlos; Segura, Ángel; Carrera, Sergio; Crespo, Guillermo; Fuster, José; Munarriz, Javier; García Alfonso, Pilar (BioMed Central, 2015-07-04)[Abstract] Background. Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine ... -
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies
Castellano, Daniel; Maroto, José Pablo; Espinosa, Enrique; Grande, Enrique; Bolós Fernández, Victoria; Llinares, Julia; Esteban, Emilio; González del Alba, Aránzazu; Climent, Miguel Ángel; Arranz, José Ángel; Méndez, María José; Fernández Parra, Eva; Antón-Aparicio, Luis M.; Bayona, Cristina; Gallegos, Isabel; Gallardo, Enrique; Samaniego, Luz; García Donas, Jesús (Taylor & Francis, 2017-08-28)[Abstract] Background: A pivotal, randomized, phase III trial demonstrated a statistically significant superiority of sunitinib over interferon-α in metastatic renal cell carcinoma (mRCC) patients. Objective: To evaluate ...